MK-6482 | Friends of Cancer Research

You are here

MK-6482

Sponsor: 
Merck Sharpe & Dohme Corp.
Indication: 
Treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required.
Category: 
Year: 
2020
Date: 
Jul 29th
FDA Status: 
Designation Granted